OncoMatch/Clinical Trials/NCT06562192
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Is NCT06562192 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including [68Ga]Ga-NNS309 and [177Lu]Lu-NNS309 for pancreatic ductal adenocarcinoma.
Treatment: [68Ga]Ga-NNS309 · [177Lu]Lu-NNS309 — The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Colorectal Cancer
Demographics
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L, hemoglobin ≥ 9 g/dL, platelet count ≥ 100 x 10^9/L
Kidney function
Creatinine clearance ≥ 60 mL/min
Cardiac function
QT interval corrected by Fridericia's formula (QTcF) < 470 msec
Absolute neutrophil count (ANC) < 1.5 x 10^9/L, hemoglobin < 9 g/dL, or platelet count < 100 x 10^9/L; QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec; Creatinine clearance < 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Uni of Alabama at Birmingham · Birmingham, Alabama
- University of California LA · Los Angeles, California
- Stanford University Medical Center · Palo Alto, California
- Mayo Clinic Jacksonville · Jacksonville, Florida
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06562192 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify